New chief medical officer at Clavis Pharma
This article was originally published in Scrip
Clavis Pharma (Norway) has appointed Dr Athos Gianella-Borradori chief medical officer. Dr Gianella-Borradori is an onco-haematologist and drug developer, having spent the past 20 years in industry, focused on translational research and on the clinical development of anticancer agents. During this career, he has held managerial and senior clinical R&D roles at Novartis, Crucell, Bavarian Nordic, Cyclacel and, for the last five years, at Serono (later at Merck Serono). Dr Gianella-Borradori's primary role at Clavis will be to drive the clinical development of, elacytarabine, which is in Phase III for patients with acute myeloid leukaemia, and of CP-4126 in partnership with Clovis Oncology, which is in Phase II development for patients with pancreatic cancer.